Dyschromicum Perstans: A Comprehensive Review of Clinical Indicators, Disease Activity, and Treatment Implications
Background: Erythema dyschromicum perstans (EDP) is an acquired, slowly progressive dermal hyperpigmentation that produces ash- grey to blue-grey macules, predominantly in patients with intermediate to dark skin phototypes. A transient erythematous border, interface inflammation and pigment incontinence are described, but most patients are seen with persistent grey macules. Whether a given lesion is still inflamed, or merely retains dermal pigment from earlier injury, is rarely documented, yet the distinction underlies treatment choice and the interpretation of treatment response. Objective: To examine whether clinical, dermoscopic, histopathological and longitudinal findings can distinguish ongoing inflammatory activity from residual pigmentation in EDP, and how this distinction should inform treatment selection, response assessment and follow-up. Evidence synthesis: PubMed (all 233 records indexed under 'erythema dyschromicum perstans' or 'ashy dermatosis'), Crossref, publisher and registry sources were searched to 26 October 2026, with backward citation chasing. Studies were classified by diagnostic terminology (EDP, ashy dermatosis, acquired dermal macular hyperpigmentation [ADMH], lichen planus pigmentosus, mixed), and each candidate activity marker was graded by the directness of its evidence. Key findings: No validated EDP-specific activity definition, activity score or histological staging system was identified. The erythematous border, which consensus terminology ties to an 'active stage', was present in only 17.6% of 68 Korean patients. New or enlarging lesions are the most pragmatic activity indicators; in an ADMH trial using this definition, stabilisation occurred after a mean of about 6 weeks, whereas pigment severity first fell significantly at week 16. Cross-sectional biopsies describe interface change and lymphocytic infiltrates in early or bordered lesions and melanophage-predominant pigment later, but no study has followed the same lesion histologically. A pinkish-brown dermoscopic background was linked to early lesions in one small series. Treatment evidence consists largely of case reports and small uncontrolled series that seldom record baseline activity or separate suppression of new lesions from pigment clearance. Conclusion: Persistent pigmentation does not by itself indicate ongoing inflammation, and absence of erythema does not exclude microscopic activity. Until prospective, activity-stratified studies exist, clinicians and investigators should document activity (new lesions, enlargement, border erythema) separately from pigment severity and should report these outcomes independently.
Authors
- Saud Abdullah Ali Alsharif
Publication Details
- Journal
- HAL
- Published
- 2026-11-14
- DOI
- https://doi.org/10.59324/jcpmr.2026.2(6).07
- Primary Topic
- melanin and skin pigmentation
- Type
- article
- Field-Weighted Citation Impact
- 0.00